Xencor (XNCR) has struggled this year, but the stock quietly jumped nearly 50% over the past quarter. This move is drawing fresh attention to whether its antibody platform and licensing deals might be...
Source LinkXencor (XNCR) has struggled this year, but the stock quietly jumped nearly 50% over the past quarter. This move is drawing fresh attention to whether its antibody platform and licensing deals might be...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.